Skip to content
AnalystLens

Medpace Holdings Annual Report, Year Ended Dec 31, 2019

Filing Date
Filed February 25, 2020
Period End
December 31, 2019
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’16Dec ’16
  2. Leadership change8-K · Apr ’19Apr ’19
  3. Material agreement8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jun ’26Jun ’26

Summary

Summary of the 10-K filed February 25, 2020. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. is one of the world's leading clinical contract research organizations by revenue, focused solely on outsourced clinical development services for biotechnology, pharmaceutical and medical device companies.

In 2019 total revenue rose to $860,969 thousanda (about $861.0 million) from $704,589 thousand in 2018, driven primarily by strong activity in Oncology and other uncategorized therapeutic areas. Income from operations was $127,263 thousand, and net income was $100,443 thousand, or $2.67 per diluted share, compared with $73,185 thousand, or $1.97 per diluted share, in 2018. Net cash provided by operating activities was $201,867 thousand.

Backlog grew to $1,283.2 millionb at December 31, 2019, up from $1,057.9 million, and net new business awards under ASC 606 were $1,094.4 million for 2019 versus $899.4 million for 2018. The company expects approximately $695 million to $715 million of backlog to convert to net revenue in 2020. The filing also notes concentration risk: the top 10 customers accounted for 28.8% of 2019 net revenue, the largest customer for 7.0%, and small biopharmaceutical companies for 71% of net revenue.

Most customer contracts can be terminated without cause on 30 days' notice. The balance sheet at year-end 2019 showed cash and cash equivalents of $131,920 thousandc and no outstanding debt under a new $50.0 million unsecured revolving Credit Facility. The company reports that it ceased to be an emerging growth company as of year-end 2019 and that August J.

Troendle, its founder and CEO, controls approximately 23.2%d of outstanding common stock. The company also remediated a material weakness related to ASC 606 implementation identified at December 31, 2018.

Key Highlights

  1. Total revenue rose to $860,969 thousand in 2019, up from $704,589 thousand in 2018, primarily driven by Oncology and other uncategorized therapeutic areas.
  2. Net income increased to $100,443 thousand ($2.67 diluted EPS) from $73,185 thousand ($1.97 diluted EPS) in 2018.
  3. Backlog increased to $1,283.2 million at December 31, 2019 from $1,057.9 million, with approximately $695 million to $715 million expected to convert to net revenue in 2020.
  4. Net new business awards were $1,094.4 million on an ASC 606 basis for 2019, compared with $899.4 million for 2018.
  5. Customer concentration is a risk: the top 10 customers represented 28.8% of 2019 net revenue, and the largest customer 7.0%; small biopharmaceutical companies contributed 71% of net revenue.
  6. Operating cash flow was $201,867 thousand, and the company had no outstanding debt at year-end 2019 under its new $50.0 million unsecured Credit Facility.
  7. Founder and CEO August J. Troendle controls approximately 23.2% of outstanding common stock, giving him significant influence over corporate actions.

Financial Statements

FY2019 against FY2018

Line itemFY2019FY2018Change
Revenue$860.97M$704.59M+22.2%
SG&A Expenses$95.25M$75.68M+25.9%
Operating Expenses$733.71M$603.54M+21.6%
Operating Income$127.26M$101.05M+25.9%
Net Income$100.44M$73.19M+37.2%
EPS (Basic)$2.79$2.05+36.1%
EPS (Diluted)$2.67$1.97+35.5%
Shares Outstanding (Basic)35.88M35.55M+0.9%
Shares Outstanding (Diluted)37.58M36.91M+1.8%

Frequently Asked Questions

  1. How did Medpace perform financially in 2019?

    Total revenue was $860,969 thousand, up from $704,589 thousand in 2018, and income from operations was $127,263 thousand, up from $101,048 thousand. Net income was $100,443 thousand, or $2.67 per diluted share, compared with $73,185 thousand, or $1.97 per diluted share, a year earlier.

  2. What is the company's backlog and how much is expected to convert to revenue in 2020?

    Backlog was $1,283.2 million at December 31, 2019, up from $1,057.9 million a year earlier. Approximately $695 million to $715 million is expected to convert to net revenue in 2020, with the remainder expected in later years. The filing cautions that backlog may not be a reliable indicator of future revenue because contracts are generally terminable without cause.

  3. How concentrated is Medpace's customer base?

    The company had no customer representing 10% or more of 2019 net revenue, but the top 10 customers accounted for 28.8% of net revenue and the largest customer for 7.0%. Small biopharmaceutical companies generated 71% of net revenue and mid-sized companies 19%. Most customers can terminate contracts without cause on 30 days' notice.

  4. What is the company's debt and liquidity position?

    At December 31, 2019 the company had cash and cash equivalents of $131.9 million and no borrowings outstanding. It entered a new unsecured Credit Facility on September 30, 2019 providing up to $50.0 million of revolving credit, which replaced its prior $165.0 million term loan and $150.0 million revolving facility. Approximately $49.8 million was available for borrowing at year-end, and management believes sources of liquidity are sufficient for the next 12 months.

  5. Who controls Medpace and what does that mean for shareholders?

    Founder and CEO August J. Troendle, through direct ownership and beneficial ownership of shares held by Medpace Investors LLC, controls approximately 23.2% of outstanding common stock as of December 31, 2019. The filing states he can exert significant influence over the election of directors, charter and bylaw amendments, and approval of mergers and other significant transactions, regardless of how other shareholders vote.